$VNRX News

Last published 2d ago

2d agoVNRXVolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business UpdatePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 13 at 8.30 a.m. U....
2w agoVNRXVolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis WorldwidePR NewswireHENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent
2w agoVNRXVolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in CashPR NewswireReduces outstanding principal to only $0.7 million on the $2.4 million note and brings total debt reduction across both notes to over $5.0 million since June 30, 2026.Secures agreement pausing conversion rights until
1mo agoVNRXVolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in FrancePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the...
1mo agoVNRXVolitionRx Participates in Launch of DETECSEPS Program in FrancePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) (XASE: VNRX) (together with affiliates, "Volition"), a multi-national epigenetics company, today announces,...
1mo agoVNRXVolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027PR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the...
2mo agoVNRXVolition Presents Early Stage I Solid Cancer Detection at the ESMO MAP ConferencePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the...
2mo agoVNRXVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update...
2mo agoVNRXVolition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in SepsisPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper ...
2mo agoVNRXVolitionRx Limited Second Quarter 2026 Financial Results and Business Update - VOLITIONRX LTDEarnings Call TranscriptsHello everyone and thank you for standing by. Welcome to VolitionRx Limited's second quarter 2026 earnings conference call. During today's presentation all parties will be in a listen-only mode. Following the presentatio
3mo agoVNRXVolitionRx Limited Announces Second Quarter 2026 Financial Results and Business UpdatePR NewswireConference call to discuss financial and operational results scheduled forFriday, August 14 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., Aug. 13, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX)
3mo agoVNRXVolition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis PatientsPR NewswireRemoves Centralized Lab Dependency for $3.8 Billion Global Addressable Market forNETosis TestingHENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national
3mo agoVNRXVolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business UpdatePR NewswireConference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., Aug. 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a
3mo agoVNRXVolition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy TechnologyPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis...
3mo agoVNRXVolition Advances Nu.Q® NETs Platform Towards CommercializationPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the...
4mo agoVNRXVolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer TestPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study...
4mo agoVNRXVolitionRx Announces Collaboration with SysmexPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a...
5mo agoVNRXVolitionRx Announces Pricing of $4.6 Million Public OfferingPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced...
5mo agoVNRXVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust...
5mo agoVNRXVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update...
6mo agoVNRXVolitionRx Limited First Quarter 2026 Financial Results and Business UpdateVOLITIONRX LTDEarnings Call TranscriptsHello everyone. Thank you for standing by. Welcome to VolitionRx Limited's first quarter 2026 earnings conference call. During today's presentation, all parties will be in a listen only mode. Following the presentation,
6mo agoVNRXVolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdatePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update...
6mo agoVNRXVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdatePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, May 15 at 8.30 a.m. U.S. Eastern ...
6mo agoVNRXVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical...
6mo agoVNRXVolition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the...
6mo agoVNRXVolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, ...
6mo agoVNRXVolition Launches rNuQ™ Webshop Broadening Product RangePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a...
7mo agoVNRXVolitionRx Limited Fourth Quarter and Full Fiscal 2025 Financial Results and Business UpdateVOLITIONRX LTDEarnings Call TranscriptsGood morning, ladies and gentlemen, and thank you for standing by. Welcome to Volition Rx Limited Full Fiscal Year 2025 Earnings Call. During today's presentation, all parties will be in a listen-only mode. Following the
7mo agoVNRXVolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdatePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update...
7mo agoVNRXVolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2....
7mo agoVNRXVolition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma PatientsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript...
7mo agoVNRXVolition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer ConferencePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the...
7mo agoVNRXVolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business UpdatePR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S....
7mo agoVNRXVolition Announces Detection of Over 95% of Early-Stage CancersPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a...
7mo agoVNRXVolition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNAPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis...
8mo agoVNRXVolition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet SystemsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and...
8mo agoVNRXVolitionRx Highlights Commercial Momentum and Multi-Pillar ExecutionPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the...
9mo agoVNRXVolition Announces the Appointment of New Distributor for Nu.Q® DiscoverPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological...
9mo agoVNRXVolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6,...
9mo agoVNRXVolition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa FoundationPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European ...
9mo agoVNRXVolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer AssaysPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement...
9mo agoVNRXVolition Announces Data to Support Use of Nu.Q® NETs in New IndicationPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the release of a new clinical study...
9mo agoVNRXVolition Continues to Extend Access to Nu.Q® Vet Cancer TestPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized...
9mo agoVNRXVolition Sponsors Symposium at Veterinary Meeting and ExpoPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at...
10mo agoVNRXVolitionRx Secures $2.0 Million in FundingPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered...
10mo agoVNRXVolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in CatsPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating...
10mo agoVNRXVolition Issues Business Review 2025PR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by...
11mo agoVNRXVolition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) EnrichmentPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript...
11mo agoVNRXVolition Announces Two Abstracts were Presented at the North America Conference on Lung CancerPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North ...
11mo agoVNRXVolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of SepsisPR NewswireVolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1...